Patents by Inventor Mark A. Kay

Mark A. Kay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190304238
    Abstract: An intelligent shelf comprising: a top platform; an electronics module including: one or more sensors for sensing presence of content on the top platform; a wireless communication chip for enabling data communication over a network; a display screen for displaying dynamic messages based on the data communication and the sensing.
    Type: Application
    Filed: March 28, 2019
    Publication date: October 3, 2019
    Applicant: Keenwawa, Inc.
    Inventors: Matthew J Ambauen, May Kay Cheung, Jacob Riddley Felser, Marina Isabel Fernandez Rodriguez, Ryan Wertz Fletcher, Jason Fruy, Seth Heltsley, Aaron Michael Kolysko, Justin Scott Laughland, Nora Naranjo, Corrine Savaiano, Mark Edward Fleschler, Michael Terry Brust, Sara Katherine Vredevoogd, Gregory Donald Giacovelli, JR., Ana Maria Varela, Jeffrey Todd Spitulnik, Thien Hua Truong
  • Patent number: 10406244
    Abstract: The present invention relates to AAV vectors encoding variant capsid polypeptides that are more cationic as compared to a non-variant parent capsid polypeptide and/or another variant capsid polypeptide, and wherein the vector comprising the variant capsid polypeptide is capable of comprising a longer nucleic acid insert as compared to a vector encoding a non-variant parent capsid polypeptide and/or another variant capsid polypeptide.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: September 10, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Matt Tiffany
  • Patent number: 10385320
    Abstract: The present invention relates to variant AAV capsid polypeptides, wherein the variant AAV capsid polypeptides exhibit increased transduction and/or tropism in human muscle tissue or cells as compared non-variant parent capsid polypeptides.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: August 20, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Nicole K. Paulk
  • Patent number: 10364595
    Abstract: A fixture lock is provided to lock two movable parts of a fixture so that one part may not be moved relative to another part to gain access to a receptacle formed in the fixture. The fixture lock could be used to lock a cabinet drawer in a closed position in a cabinet base to block access to a storage region formed in the cabinet drawer.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: July 30, 2019
    Assignee: Dorel Juvenile Group, Inc.
    Inventors: Brian C Sundberg, Laura Kay Raffi, Alice Mayfield, Scott E Stropkay, Mark Matthews, Evan Hutker
  • Patent number: 10294697
    Abstract: An access-control system is provided for a door lock that is associated with a door and a rotatable doorknob. The access-control system includes a doorknob cover.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: May 21, 2019
    Assignee: Dorel Juvenile Group, Inc.
    Inventors: Brian C Sundberg, Laura Kay Raffi, Alice Mayfield, Scott E Stropkay, Mark Matthews, Evan Hutker
  • Patent number: 10179176
    Abstract: The present invention relates to variant AAV capsid polypeptides, wherein the variant capsid polypeptides exhibit an enhanced neutralization profile, increased transduction and/or tropism in human liver tissue or hepatocyte cells (i.e., human hepatocyte cells), or both, as compared non-variant parent capsid polypeptides.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: January 15, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Nicole K. Paulk
  • Publication number: 20190010517
    Abstract: Compositions and methods are provided for inducing/enhancing homologous recombination (HR) in a target cell (e.g., for editing a genome). In some embodiments, a subject method includes introducing into a cell: (a) a donor DNA (e.g., via a virus such as AAV); and (b) an agent that inhibits expression and/or function of an endogenous gene (e.g., an RNAi agent, a genome editing agent, a chemical inhibitor). In some cases, the endogenous gene is selected from: FANCM, DDX28, PCBP1, SFRS1/SRSF1, CDK19, DNAJA3/TID1, CDC16, CDT1, SASS6, SPC24, CENPM, MCM2, KLHL9, MYBBP1A, NUP85, NUP88, KIF4A, MASTL, CRLF3, SET, GABPB1, PSMB4, THAP6, COPZ1, RMI1, BLM, TOP3A, and RM12. In some embodiments, a subject method includes introducing into a target cell: (a) a donor DNA (e.g., via a virus such as AAV); and (b) an agent that inhibits centriole/centrosome assembly (e.g., an inhibitor of Polo-like kinase 4 (Plk4), centrinone, centrinone B, CFI-400945, R1530, and the like).
    Type: Application
    Filed: June 29, 2018
    Publication date: January 10, 2019
    Inventors: Mark A. Kay, Gustavo De Alencastro
  • Publication number: 20180258420
    Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.
    Type: Application
    Filed: December 1, 2017
    Publication date: September 13, 2018
    Inventors: Leszek Lisowski, Mark A. Kay
  • Publication number: 20180251783
    Abstract: Provided are nucleic acids and expression vectors having a non-silencing selectable marker gene, and methods of using the same. A subject expression vector includes an expression cassette and a non-silencing selectable marker gene. In some cases, the non-silencing selectable marker gene provides for drug resistance for prokaryotic cells, and includes a nucleotide sequence that (i) encodes a drug selectable marker protein; (ii) is operably linked to a promoter functional in prokaryotic cells, and (iii) includes an increased A/T content relative to a corresponding wild type nucleotide sequence. In some cases, the non-silencing selectable marker gene provides for drug resistance for prokaryotic cells, and includes a nucleotide sequence that (i) encodes a drug selectable marker protein; (ii) is operably linked to a promoter functional in prokaryotic cells, and (iii) has an A/T content in a range of from 52% to 70%.
    Type: Application
    Filed: May 2, 2018
    Publication date: September 6, 2018
    Inventors: Mark A. Kay, Jiamiao Lu
  • Patent number: 10006047
    Abstract: Provided are nucleic acids and expression vectors having a non-silencing selectable marker gene, and methods of using the same. A subject expression vector includes an expression cassette and a non-silencing selectable marker gene. In some cases, the non-silencing selectable marker gene provides for drug resistance for prokaryotic cells, and includes a nucleotide sequence that (i) encodes a drug selectable marker protein; (ii) is operably linked to a promoter functional in prokaryotic cells, and (iii) includes an increased A/T content relative to a corresponding wild type nucleotide sequence. In some cases, the non-silencing selectable marker gene provides for drug resistance for prokaryotic cells, and includes a nucleotide sequence that (i) encodes a drug selectable marker protein; (ii) is operably linked to a promoter functional in prokaryotic cells, and (iii) has an A/T content in a range of from 52% to 70%.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: June 26, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Jiamiao Lu
  • Publication number: 20180163229
    Abstract: The present invention relates to variant AAV capsid polypeptides containing designed ankyrin repeat proteins (DARPins), wherein the variant capsid polypeptides exhibit an enhanced neutralization profile, increased transduction, and/or tropism in human liver and/or hepatocyte cells, or human pancreas and/or pancreatic cells, as compared to capsid polypeptides that do not include DARPins.
    Type: Application
    Filed: December 11, 2017
    Publication date: June 14, 2018
    Inventors: Mark A. Kay, Robert C. Muench
  • Publication number: 20180051300
    Abstract: The teachings herein are generally directed to a method of enhancing the genetic stability of parvovirus vectors. The stability of conventional ss or dsAAV vector constructs can be enhanced, for example, to obtain a concurrent increase in vector titer and purity, as well as an improvement in vector safety, due at least in part to the elimination of stuffer DNA from the AAV vector. The method is broadly applicable to all gene transfer/therapy applications, such as those requiring delivery of foreign DNA containing recombinant gene expression cassettes. Such foreign DNA can range, for example, from about 0.2 up to about 5.2 kb in length. The enhanced vector constructs are highly flexible, user-friendly, and can be easily modified (via routine DNA cloning) and utilized (via standard AAV vector technology) by anyone skilled in the art.
    Type: Application
    Filed: September 15, 2017
    Publication date: February 22, 2018
    Inventors: Mark A. Kay, Dirk Grimm
  • Publication number: 20180010135
    Abstract: Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an expression cassette. Also provided are methods of using the subject vectors for introduction of a nucleic acid, e.g., an expression cassette, into a target cell, as well as preparations for use in practicing such methods. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications. Also provided is a highly efficient and readily scalable method for producing the vectors employed in the subject methods, as well as reagents and kits/systems for practicing the same.
    Type: Application
    Filed: July 18, 2017
    Publication date: January 11, 2018
    Inventors: Mark A. Kay, Zhi-Ying Chen
  • Patent number: 9856469
    Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: January 2, 2018
    Assignee: The Board of Trustees of The Leland Stanford Junior University
    Inventors: Leszek Lisowski, Mark A. Kay
  • Publication number: 20170360962
    Abstract: The present invention relates to variant AAV capsid polypeptides, wherein the variant capsid polypeptides exhibit an enhanced neutralization profile, increased transduction and/or tropism in human liver tissue or hepatocyte cells (i.e., human hepatocyte cells), or both, as compared non-variant parent capsid polypeptides.
    Type: Application
    Filed: August 18, 2017
    Publication date: December 21, 2017
    Inventors: Mark A. Kay, Nicole K. Paulk
  • Publication number: 20170348433
    Abstract: The present invention relates to variant AAV capsid polypeptides, wherein the variant capsid polypeptides exhibit an enhanced neutralization profile, increased transduction and/or tropism in human liver tissue or hepatocyte cells (i.e., human hepatocyte cells), or both, as compared non-variant parent capsid polypeptides.
    Type: Application
    Filed: February 16, 2017
    Publication date: December 7, 2017
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. KAY, Nicole K. PAULK
  • Patent number: 9783824
    Abstract: The teachings herein are generally directed to a method of enhancing the genetic stability of parvovirus vectors. The stability of conventional ss or dsAAV vector constructs can be enhanced, for example, to obtain a concurrent increase in vector titer and purity, as well as an improvement in vector safety, due at least in part to the elimination of stuffer DNA from the AAV vector. The method is broadly applicable to all gene transfer/therapy applications, such as those requiring delivery of foreign DNA containing recombinant gene expression cassettes. Such foreign DNA can range, for example, from about 0.2 up to about 5.2 kb in length. The enhanced vector constructs are highly flexible, user-friendly, and can be easily modified (via routine DNA cloning) and utilized (via standard AAV vector technology) by anyone skilled in the art.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: October 10, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Dirk Grimm
  • Patent number: 9745590
    Abstract: Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an expression cassette. Also provided are methods of using the subject vectors for introduction of a nucleic acid, e.g., an expression cassette, into a target cell, as well as preparations for use in practicing such methods. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications. Also provided is a highly efficient and readily scalable method for producing the vectors employed in the subject methods, as well as reagents and kits/systems for practicing the same.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: August 29, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Zhi-Ying Chen
  • Publication number: 20170233765
    Abstract: Compositions and methods are provided for integrating one or more genes of interest into cellular DNA without substantially disrupting the expression of the gene at the locus of integration, i.e., the target locus. These compositions and methods are useful in any in vitro or in vivo application in which it is desirable to express a gene of interest in the same spatially and temporally restricted pattern as that of a gene at a target locus while maintaining the expression of the gene at the target locus, for example, to treat disease, in the production of genetically modified organisms in agriculture, in the large scale production of proteins by cells for therapeutic, diagnostic, or research purposes, in the induction of iPS cells for therapeutic, diagnostic, or research purposes, in biological research, etc. Reagents, devices and kits thereof that find use in practicing the subject methods are also provided.
    Type: Application
    Filed: March 13, 2017
    Publication date: August 17, 2017
    Inventors: Mark A. Kay, Matthew Porteus, Jenny Barker, Josh Checketts, Richard Voit, Adi Barzel
  • Patent number: 9701981
    Abstract: The silencing effect of a spacer sequence, for example a bacterial backbone sequence in a plasmid or other episomal vector, on transgene expression is reversed by engineering of the spacer to include nucleosome exclusion sequences.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: July 11, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jiamiao Lu, Mark A. Kay, Andrew Fire, Lia E. Gracey Maniar